(ANIK) Anika Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0352551081

Pain Management, Joint Restoration, Joint Preservation, Orthopedic Implants

ANIK EPS (Earnings per Share)

EPS (Earnings per Share) of ANIK over the last years for every Quarter: "2020-03": 0.24, "2020-06": -0.54, "2020-09": -0.45, "2020-12": -1.1, "2021-03": 0.2, "2021-06": 0.45, "2021-09": 0.04, "2021-12": -0.4, "2022-03": -0.2, "2022-06": -0.2, "2022-09": -0.29, "2022-12": -0.34, "2023-03": -0.71, "2023-06": -0.19, "2023-09": -0.45, "2023-12": -4.3, "2024-03": -0.31, "2024-06": -0.01, "2024-09": -2.03, "2024-12": -1.49, "2025-03": -0.34,

ANIK Revenue

Revenue of ANIK over the last years for every Quarter: 2020-03: 35.397, 2020-06: 30.678, 2020-09: 31.694, 2020-12: 32.688, 2021-03: 34.292, 2021-06: 38.145, 2021-09: 39.536, 2021-12: 35.821, 2022-03: 36.693, 2022-06: 39.657, 2022-09: 40.264, 2022-12: 39.622, 2023-03: 37.924, 2023-06: 44.302, 2023-09: 41.465, 2023-12: 42.971, 2024-03: 40.523, 2024-06: 41.921, 2024-09: 38.753, 2024-12: -1.29, 2025-03: 26.168,

Description: ANIK Anika Therapeutics

Anika Therapeutics Inc. is a joint preservation company that develops, manufactures, and commercializes innovative products based on its proprietary hyaluronic acid (HA) technology platform, targeting osteoarthritis pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions. The companys product portfolio includes injectable viscosupplements like Monovisc and Orthovisc, as well as Cingal, a single-injection OA pain management product. Anikas joint preservation and restoration product family encompasses orthopedic regenerative solutions, sports medicine solutions, and preserving joint solutions, including partial joint replacement and joint resurfacing implants.

The companys diverse product offerings also extend to non-orthopedic applications, including veterinary products like Hyvisc, anti-adhesion barriers like Hyalobarrier, and treatments for burns, ulcers, and ear, nose, and throat disorders. With a strong foundation in HA technology, Anika Therapeutics has established itself as a leader in the orthopedic and regenerative medicine markets. The companys commitment to innovation and early intervention orthopedic care has enabled it to expand its global presence, with products available in the United States, Europe, and internationally.

Analyzing the provided technical data, ANIKs current price is 12.41, with its 20-day SMA at 13.95, 50-day SMA at 14.79, and 200-day SMA at 19.26, indicating a downtrend. The ATR of 0.85 represents a 6.84% volatility. Given the current trend and the fact that the stock is trading near its 52-week low of 11.64, a potential support level, it is likely that the stock will experience a bounce or consolidation in the near term. However, the long-term trend remains bearish, and a break below the 52-week low could lead to further declines.

Combining the technical analysis with fundamental data, ANIKs market capitalization stands at 166.93M USD, with a forward P/E ratio of 46.73, indicating high growth expectations. However, the companys RoE of -29.96 suggests significant losses. To forecast the stocks performance, we can consider the potential impact of new product launches, such as Cingal, and the companys expanding presence in the regenerative medicine market. If Anika Therapeutics can demonstrate improved profitability and growth, the stock may experience a re-rating, potentially driving the price towards the 20-day SMA of 13.95. However, failure to address the current losses and improve profitability could lead to further declines, potentially testing the 52-week low.

Additional Sources for ANIK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

ANIK Stock Overview

Market Cap in USD 161m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Biotechnology
IPO / Inception 1993-04-29

ANIK Stock Ratings

Growth Rating -85.3
Fundamental -44.3
Dividend Rating 0.0
Rel. Strength -53.1
Analysts 4.67 of 5
Fair Price Momentum 7.14 USD
Fair Price DCF -

ANIK Dividends

Currently no dividends paid

ANIK Growth Ratios

Growth Correlation 3m -85.5%
Growth Correlation 12m -94%
Growth Correlation 5y -80%
CAGR 5y -20.87%
CAGR/Max DD 5y -0.27
Sharpe Ratio 12m -0.69
Alpha -68.48
Beta 0.773
Volatility 52.88%
Current Volume 144k
Average Volume 20d 55.3k
Stop Loss 10.4 (-5.3%)
What is the price of ANIK shares?
As of July 09, 2025, the stock is trading at USD 10.98 with a total of 144,047 shares traded.
Over the past week, the price has changed by +4.27%, over one month by -4.69%, over three months by -16.44% and over the past year by -57.39%.
Is Anika Therapeutics a good stock to buy?
Probably not. Based on ValueRay´s Fundamental Analyses, Anika Therapeutics (NASDAQ:ANIK) is currently (July 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.33 and therefor a somewhat negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ANIK is around 7.14 USD . This means that ANIK is currently overvalued and has a potential downside of -34.97%.
Is ANIK a buy, sell or hold?
Anika Therapeutics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ANIK.
  • Strong Buy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for ANIK share price target?
According to our own proprietary Forecast Model, ANIK Anika Therapeutics will be worth about 8.5 in July 2026. The stock is currently trading at 10.98. This means that the stock has a potential downside of -22.5%.
Issuer Target Up/Down from current
Wallstreet Target Price 21.3 94.3%
Analysts Target Price 21.3 94.3%
ValueRay Target Price 8.5 -22.5%